Flexible evaluation of surrogacy in Bayesian adaptive platform studies

TL;DR

This paper introduces a flexible hierarchical Bayesian semiparametric model for evaluating trial level surrogates specifically in Bayesian adaptive platform studies, addressing heterogeneity and clustering issues.

Contribution

It proposes a novel nonparametric Bayesian approach for surrogate evaluation that accounts for heterogeneity and identifies differential surrogate value clusters.

Findings

Proposed method outperforms standard hierarchical Bayesian models in simulations.

The approach can identify clusters with different surrogate utility.

Application to simulated ProBio trial demonstrates practical utility.

Abstract

Trial level surrogates are useful tools for improving the speed and cost effectiveness of trials, but surrogates that have not been properly evaluated can cause misleading results. The evaluation procedure is often contextual and depends on the type of trial setting. There have been many proposed methods for trial level surrogate evaluation, but none, to our knowledge, for the specific setting of Bayesian adaptive platform studies. As adaptive studies are becoming more popular, methods for surrogate evaluation using them are needed. These studies also offer a rich data resource for surrogate evaluation that would not normally be possible. However, they also offer a set of statistical issues including heterogeneity of the study population, treatments, implementation, and even potentially the quality of the surrogate. We propose the use of a hierarchical Bayesian semiparametric model for the evaluation of potential surrogates using nonparametric priors for the distribution of true effects based on Dirichlet process mixtures. The motivation for this approach is to flexibly model relationships between the treatment effect on the surrogate and the treatment effect on the outcome and also to identify potential clusters with differential surrogate value in a data-driven manner. In simulations, we find that our proposed method is superior to a simple, but fairly standard, hierarchical Bayesian method. We demonstrate how our method can be used in a simulated illustrative example (based on the ProBio trial), in which we are able to identify clusters where the surrogate is, and is not useful. We plan to apply our method to the ProBio trial, once it is completed.